Loading stock data…
Alumis Inc. (ALMS)
$26.38-0.02 (-0.09%)
Market OpenUpdated 2:03 PM EDT
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alumis Inc. in the Healthcare sector is trading at $26.38 with a market capitalization of $2.6B. Wall Street consensus targets $40.10 (10 analysts), implying a +52.0% move over the next 12 months. The stock is currently near its 52-week high of $30.60, remaining 53.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.74M↓ | $1.93M↓ | $2.07M↓ | $2.67M↓ | $17.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$98.41M↓ | -$96.44M↑ | -$115.29M↑ | -$140.54M↓ | -$101.53M |
| Net Income | -$93.05M↓ | -$92.93M↑ | -$110.75M↓ | $59.32M↑ | -$98.96M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psori...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.87%
Volume
Today's trading volume
863,330
Recent News
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements
With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026. Alumis Inc. (NASDAQ:ALMS) drew three analyst price target raises after reporting Q1 results and advancing its envudeucitinib pipeline toward a pair of major readouts. On May 19, 2026, Chardan raised its price target to $40 […]
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
Alumis Inc. recently reported first-quarter 2026 results, with revenue of US$1.74 million versus US$17.39 million a year earlier and a net loss of US$93.05 million compared with US$98.96 million previously. Despite sharply lower revenue, the company’s narrower loss per share suggests cost discipline and operational adjustments are becoming more visible in its financials. Next, we’ll examine how Alumis’ reduced net loss shapes its investment narrative and what it may signal about the business...
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.